Ryvu Therapeutics Stock

Ryvu Therapeutics EBIT

The EBIT of Ryvu Therapeutics (RVU.WA) as of Aug 8, 2026 is -121.97 M PLN. In the previous year, EBIT was -97.38 M PLN — a change of 25.26% (lower).

EBIT

-121.97 MPLN

YoY

25.26%

Last updated:

In 2026, Ryvu Therapeutics's EBIT was -121.97 M PLN, a 25.26% increase from the -97.38 M PLN EBIT recorded in the previous year.

The Ryvu Therapeutics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M PLN)
Date
EBIT (M PLN)
Jan 1, 2023
-97.38 base
Jan 1, 2024
-121.97 base
Jan 1, 2025 (e)
-84.18 base
Jan 1, 2026 (e)
-110.40 base
Jan 1, 2027 (e)
-106.88 base
Jan 1, 2028 (e)
-141.00 base
Jan 1, 2029 (e)
-27.00 base
Jan 1, 2030 (e)
-107.00 base
YEAREBIT (M PLN)
2030 est -107.00
2029 est -27.00
2028 est -141.00
2027 est -106.88
2026 est -110.40
2025 est -84.18
2024 -121.97
2023 -97.38
2022 -70.69
2021 -78.89
2020 -35.67
2019 -45.39
2018 -13.62
2017 12.66
2016 -1.22
2015 2.07
2014 5.27
2013 -2.23
2012 -6.12
Access this data via the Eulerpool API

Ryvu Therapeutics Revenue

Ryvu Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
46.86 M PLN
-97.38 M PLN
-92.11 M PLN
Jan 1, 2024
77.97 M PLN
-121.97 M PLN
-111.44 M PLN
Jan 1, 2025 (e)
84.18 M PLN
-84.18 M PLN
-107.62 M PLN
Jan 1, 2026 (e)
110.40 M PLN
-110.40 M PLN
-50.40 M PLN
Jan 1, 2027 (e)
106.88 M PLN
-106.88 M PLN
-2.54 M PLN
Jan 1, 2028 (e)
141.00 M PLN
-141.00 M PLN
8.55 M PLN
Jan 1, 2029 (e)
27.00 M PLN
-27.00 M PLN
0.00 PLN
Jan 1, 2030 (e)
107.00 M PLN
-107.00 M PLN
0.00 PLN

Ryvu Therapeutics Margins

Ryvu Therapeutics stock margins

The Ryvu Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ryvu Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ryvu Therapeutics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
44.80 %
-207.80 %
-196.57 %
Jan 1, 2024
69.58 %
-156.43 %
-142.92 %
Jan 1, 2025 (e)
69.58 %
-100.00 %
-127.86 %
Jan 1, 2026 (e)
69.58 %
-100.00 %
-45.65 %
Jan 1, 2027 (e)
69.58 %
-100.00 %
-2.38 %
Jan 1, 2028 (e)
69.58 %
-100.00 %
6.07 %
Jan 1, 2029 (e)
69.58 %
-100.00 %
0.00 %
Jan 1, 2030 (e)
69.58 %
-100.00 %
0.00 %

Ryvu Therapeutics Stock analysis

What does Ryvu Therapeutics do? Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Ryvu Therapeutics's EBIT

Ryvu Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Ryvu Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Ryvu Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Ryvu Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Ryvu Therapeutics stock

EBIT of Ryvu Therapeutics is -121.97 M PLN in 2026.

EBIT of Ryvu Therapeutics changed from -97.38 M PLN to -121.97 M PLN, representing a 25.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Ryvu Therapeutics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Ryvu Therapeutics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Ryvu Therapeutics

All Key Metrics — Ryvu Therapeutics